TuHURA Biosciences, Inc. (HURA)Healthcare | Biotechnology | Tampa, United States | NasdaqCM
2.11 USD
-0.02
(-0.939%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.18 +0.07 (3.237%) ⇧ (Aug. 28, 2026, 7:46 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:20 a.m. EDT
The immediate outlook is flat due to a lack of clear directional edge, though the stock recently rallied from its lows before settling back near the fifty-day average. However, the long-term investment case is severely compromised by a brutal multi-year decline; the asset has lost virtually all its value over the last nine years, with four consecutive years of negative returns ending at the most recent anchor. This persistent downward trajectory suggests a structural deterioration in the business or a complete failure of the market to value its prospects, overriding any potential recovery narratives. Furthermore, there is no dividend income to offset these massive capital losses, making the security unsuitable for investors seeking yield or stability. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.069027 |
| MSTL | 0.069831 |
| AutoETS | 0.071554 |
| AutoARIMA | 0.081734 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 0.60 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.310 |
| Excess Kurtosis | -0.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 49.617 |
| Market Cap | 134,463,152 |
| Forward P/E | -3.49 |
| Website | https://www.tuhurabio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.18532819 |
| Address1 | 10,500 University Center Drive |
| Address2 | Suite 110 |
| All Time High | 190,225.0 |
| All Time Low | 0.41 |
| Ask | 2.63 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 225,390 |
| Average Daily Volume3 Month | 437,503 |
| Average Volume | 437,503 |
| Average Volume10Days | 225,390 |
| Bid | 2.11 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | 0.286 |
| City | Tampa |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.11 |
| Current Ratio | 0.179 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.15 |
| Day Low | 2.04 |
| Debt To Equity | 49.617 |
| Display Name | TuHURA Biosciences |
| Earnings Timestamp End | 1,794,573,000 |
| Earnings Timestamp Start | 1,794,573,000 |
| Ebitda | -30,927,138 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.621 |
| Enterprise Value | 142,925,088 |
| Eps Current Year | -0.53 |
| Eps Forward | -0.605 |
| Eps Trailing Twelve Months | -0.53 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.2625 |
| Fifty Day Average Change | -0.15250015 |
| Fifty Day Average Change Percent | -0.06740338 |
| Fifty Two Week Change Percent | -18.532818 |
| Fifty Two Week High | 3.43 |
| Fifty Two Week High Change | -1.3200002 |
| Fifty Two Week High Change Percent | -0.38483968 |
| Fifty Two Week Low | 0.41 |
| Fifty Two Week Low Change | 1.6999999 |
| Fifty Two Week Low Change Percent | 4.1463413 |
| Fifty Two Week Range | 0.41 - 3.43 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,361,543,400,000 |
| Float Shares | 39,701,045 |
| Forward Eps | -0.605 |
| Forward P E | -3.487603 |
| Free Cashflow | -18,276,332 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 22 |
| Fullday Change | -0.0200002 |
| Fullday Change Percent | -0.938977 |
| Fullday Price | 2.1783 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.34624 |
| Held Percent Institutions | 0.142 |
| Implied Shares Outstanding | 63,726,617 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,729,209,600 |
| Last Split Factor | 1:35 |
| Long Business Summary | TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc. |
| Long Name | TuHURA Biosciences, Inc. |
| Market | us_market |
| Market Cap | 134,463,152 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_9858113 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -30,632,024 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 136,374,960 |
| Number Of Analyst Opinions | 5 |
| Open | 2.15 |
| Operating Cashflow | -29,689,118 |
| Operating Margins | 0.0 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 813 875 6600 |
| Post Market Change | 0.06830001 |
| Post Market Change Percent | 3.2369673 |
| Post Market Price | 2.1783 |
| Post Market Time | 1,787,960,776 |
| Previous Close | 2.13 |
| Price Eps Current Year | -3.981132 |
| Price Hint | 4 |
| Price To Book | 7.3776217 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.14 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.0200002 |
| Regular Market Change Percent | -0.938977 |
| Regular Market Day High | 2.15 |
| Regular Market Day Low | 2.04 |
| Regular Market Day Range | 2.04 - 2.15 |
| Regular Market Open | 2.15 |
| Regular Market Previous Close | 2.13 |
| Regular Market Price | 2.11 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 99,651 |
| Return On Assets | -0.58429 |
| Return On Equity | -1.6139 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 63,726,617 |
| Shares Percent Shares Out | 0.0992 |
| Shares Short | 6,323,340 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 6,647,078 |
| Short Name | TuHURA Biosciences, Inc. |
| Short Percent Of Float | 0.1283 |
| Short Ratio | 23.75 |
| Source Interval | 15 |
| State | FL |
| Symbol | HURA |
| Target High Price | 10.0 |
| Target Low Price | 6.2 |
| Target Mean Price | 8.04 |
| Target Median Price | 8.0 |
| Total Cash | 995,977 |
| Total Cash Per Share | 0.016 |
| Total Debt | 9,179,367 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.53 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.818035 |
| Two Hundred Day Average Change | 0.2919649 |
| Two Hundred Day Average Change Percent | 0.16059366 |
| Type Disp | Equity |
| Volume | 99,651 |
| Website | https://www.tuhurabio.com |
| Zip | 33,612 |